Taken together, our results imply that MBNL1 and RC3H1 are potential regulators of exon 5–6 skipping in B-ALL patients, and attractive targets to enhance CAR-T therapy efficacy. This evidence concerns the gene MBNL1 and acute lymphoblastic leukemia.